How do SGLT2 inhibitors protect the kidney? A mediation analysis of the EMPA-REG OUTCOME trial
Nephrology Dialysis Transplantation · 30.08.2024 · 39 (9) · 1504-1513
DOI: 10.1093/ndt/gfae032 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift Nephrology Dialysis Transplantation, online erschienen am 06.02.2024. Verfasst von Christoph Wanner und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Würzburg University Clinic, Würzburg, Germany. Hauptthemen laut MEDLINE: Benzhydryl Compounds, Diabetes Mellitus, Type 2, Glomerular Filtration Rate, Glucosides. Die Arbeit wurde bisher 54-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Boehringer Ingelheim, Eli Lilly and Company.
Abstract (Originalsprache)
Introduction
Mechanisms underlying kidney benefits with sodium-glucose cotransporter-2 (SGLT2) inhibition in heart failure and/or type 2 diabetes (T2D) with established cardiovascular disease are currently unclear.
Methods
We evaluated post hoc the factors mediating the effect of empagliflozin on a composite kidney outcome (first sustained estimated glomerular filtration rate ≥40% reduction from baseline, initiation of renal replacement therapy or death due to kidney disease) in EMPA-REG OUTCOME (Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients). Variables, calculated as change from baseline or updated mean, were evaluated as time-dependent covariates and using a landmark approach (at Week 12) in Cox regression analyses. In multivariable analyses, variables with the greatest mediating effect were added using a step-up procedure.
Results
In univariable time-dependent updated mean covariate analyses, the strongest mediator was hematocrit (99.5% mediation). Hemoglobin, uric acid and urine albumin-to-creatinine ratio mediated 79.4%, 33.2% and 31.0%, respectively. Multivariable analyses were not performed due to the very strong mediation effect of hematocrit. In univariable Week 12 landmark change from baseline analyses, the strongest mediators included hematocrit (40.7%), glycated hemoglobin (28.3%), systolic blood pressure (16.8%) and free fatty acids (16.5%), which yielded a combined mediation of 78.9% in multivariable analysis.
Conclusions
Changes in hematocrit and hemoglobin were the strongest mediators of empagliflozin's kidney benefits in EMPA-REG OUTCOME participants with T2D and cardiovascular disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Würzburg University Clinic, Würzburg, Germany.
- Division of Nephrology and Endocrinology, Department of Hemodialysis and Apheresis, The University of Tokyo Hospital, Tokyo, Japan.
- Medical Affairs, Boehringer Ingelheim International GmbH, Ingelheim, Germany.
- Department of Internal Medicine I, University Hospital Würzburg, Würzburg, Germany.
- Comprehensive Heart Failure Centre, University of Würzburg, Würzburg, Germany.
- Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, ON, Canada.
ORCID-Profile: Christoph Wanner
Förderung
- Boehringer Ingelheim
- Eli Lilly and Company
Zitieren
APA
Wanner, C., Nangaku, M., Kraus, B. J., Zinman, B., Mattheus, M., Hantel, S., Schumacher, M., Ohneberg, K., Schmoor, C., & Inzucchi, S. E. (2024). How do SGLT2 inhibitors protect the kidney? A mediation analysis of the EMPA-REG OUTCOME trial. Nephrology Dialysis Transplantation, 39(9), 1504-1513. https://doi.org/10.1093/ndt/gfae032
Vancouver
Wanner C, Nangaku M, Kraus BJ, Zinman B, Mattheus M, Hantel S, et al. How do SGLT2 inhibitors protect the kidney? A mediation analysis of the EMPA-REG OUTCOME trial. Nephrology Dialysis Transplantation. 2024;39(9):1504-1513. doi:10.1093/ndt/gfae032
BibTeX
@article{Wanner2024,
author = {Wanner, Christoph and Nangaku, Masaomi and Kraus, Bettina J and Zinman, Bernard and Mattheus, Michaela and Hantel, Stefan and Schumacher, Martin and Ohneberg, Kristin and Schmoor, Claudia and Inzucchi, Silvio E},
title = {How do SGLT2 inhibitors protect the kidney? A mediation analysis of the EMPA-REG OUTCOME trial},
journal = {Nephrology Dialysis Transplantation},
year = {2024},
volume = {39},
number = {9},
pages = {1504--1513},
doi = {10.1093/ndt/gfae032}
}
EUVIMED